{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"1.900","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,386,638,336","primaryexch":"香港交易所","ric":"3681.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BKLGNM9","am":"17.74","iv":"","ew_strike":"","as":"1.780","geographic_focus":null,"incorpin":"香港","etp_baseCur":null,"ew_amt_os":"","bd":"1.760","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"300","update_time":"2025-09-28 00:06:03.0","lo52":"0.800","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"梁瑞安","underlying_ric":"3681.HK","hi52":"3.760","issuer_name":"中國抗體製藥有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"1.750","mkt_cap":"2.44","f_aum_hkd":null,"ew_sub_per_to":"","ls":"1.760","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.120","aum":"","issued_shares_class_B":null,"vo":"9.74","secondary_listing_flag":false,"listing_date":"2019年11月12日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"中國抗體製藥有限公司 - B","nm_s":"中國抗體—Ｂ","sym":"3681","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"中國抗體製藥有限公司是一家主要研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司。該公司主要研製以單克隆抗體為基礎的生物製劑和和新化學實體。該公司主要產品SM03是治療類風濕關節炎的潛在單抗藥物。該公司研發藥物用於治療類風濕關節炎、系統性紅斑狼瘡、哮喘、天皰瘡、乾燥綜合症及其他免疫性疾病。","op":"1.880","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港新界白石角<br/>香港科學園<br/>科技大道西15號<br/>303及305-307室","pc":"-6.38","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"1.880","isin":"HK0000544194","moneyness":""}},"qid":"1759074334479"}
